Annexon, Inc. (ANNX) Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration. The company's developmental pipeline features several promising candidates. ANX005, a monoclonal antibody, is in advanced clinical testing, undergoing Phase II/III trials for Guillain-Barré syndrome, as well as Phase II trials for warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis. Another candidate, ANX009, is currently in Phase Ib studies for lupus nephritis. Additionally, ANX007 is progressing through Phase II clinical trials for the treatment of geographic atrophy, an eye disease. Further investigational assets include ANX105, a monoclonal antibody being developed for neurodegenerative indications, and ANX1502, an oral small molecule under investigation for specific autoimmune conditions. Annexon, Inc. was established in 2011 and operates from its headquarters in Brisbane, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Annexon, Inc. NASDAQ:ANNX Healthcare · Biotechnology
Mkt Cap $767.8M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial
Annexon announced a virtual investor event on November 3, 2026 at 11:00 AM ET focused on the Phase 3 ARCHER II trial of vonaprument in geographic atrophy.
Management will cover trial design, patient demographics, and communication strategy ahead of anticipated 15-month and 24-month results beginning in Q4 2026.
Retina specialist Roger Goldberg will join to discuss the geographic atrophy treatment landscape. The release contains no new data or financial figures.
• 4d ago AI analysis › Press Release ⚠ 1
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon granted inducement equity awards to six new non-executive employees under its 2022 Employment Inducement Award Plan, consistent with Nasdaq Listing Rule 5635(c)(4).
The aggregate award consists of options on 1,270,000 shares with a ten-year term and a $3.60 exercise price, equal to the October 15, 2026 close, vesting over four years with a one-year cliff.
This is a routine new-hire inducement grant filing and carries no material operational or financial signal.
• 16d ago AI analysis › Press Release ⚠ 2
Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
Annexon will present Phase 3 ARCHER II patient baseline characteristics and Phase 2 vision-protection analyses at The Retina Society 59th Annual Scientific Meeting, September 23-26 in Los Angeles.
The presentations highlight consistent baseline characteristics between the Phase 2 and Phase 3 populations, positioning ARCHER II to replicate Phase 2 vision-protection outcomes with vonaprument in geographic atrophy.
The pivotal Phase 3 ARCHER II trial enrolled 659 patients, with month 15 primary analysis results expected in the fourth quarter of 2026 — the key binary catalyst for the stock.
• 1mo ago AI analysis › Press Release
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon granted inducement equity awards to two new non-executive employees under its 2022 Employment Inducement Award Plan, approved September 12, 2026.
The awards are options to purchase 275,500 shares at a $3.92 exercise price, equal to the September 15 closing price, with a ten-year term and standard four-year vesting including a 25% one-year cliff.
This is a routine Nasdaq Listing Rule 5635(c)(4) compliance disclosure with no new clinical, financial, or strategic information.
• 1mo ago AI analysis › Press Release
Annexon to Participate in Upcoming September Investor Conferences
Annexon CEO Douglas Love will participate in fireside chats at three September healthcare investor conferences.
The schedule includes the Wells Fargo 21st Annual Healthcare Conference on September 9, the Cantor Global Healthcare Conference on September 10, and the H.C. Wainwright 28th Annual Global Investment Conference on September 15.
Live webcasts will be available on the Annexon investor site, with replays archived for 30 days. The release contains no new clinical, financial, or strategic information and is routine investor-relations scheduling.
• 1mo ago AI analysis › Press Release
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon granted inducement options to three new non-executive employees as an employment incentive under Nasdaq Listing Rule 5635(c)(4).
The awards allow for the purchase of an aggregate of 287,500 shares at an exercise price of $5.29 per share, which was the closing price on the grant date.
Options vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter.
• 2mo ago AI analysis › Press Release
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
Annexon reported positive clinical progress across its pipeline, including rapid outcomes in the GBS FORWARD study and strategic enhancements to the Vonaprument Phase 3 ARCHER II trial with a new dual primary endpoint at Month 24.
Financially, the company secured a $200 million credit facility with an initial $50 million draw, extending its cash runway into 2028 to support ongoing operations and anticipated milestones.
Key upcoming milestones include a Biologics License Application (BLA) submission for tanruprubart in Q4 2026 and the Month 15 primary endpoint readout for Vonaprument in Q4 2026.
• 2mo ago AI analysis › Press Release
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
Annexon has added a Month 24 dual primary endpoint to its ongoing Phase 3 ARCHER II trial of vonaprument for geographic atrophy, allowing the trial to succeed at either Month 15 or Month 24.
The company also launched an open-label extension study and reported that the trial maintains strong statistical power with high patient compliance (>95%) and a low discontinuation rate (<10%).
Topline results for the Month 15 primary analysis are expected in the fourth quarter of 2026, with full completion of the trial anticipated in the third quarter of 2027.
• 2mo ago AI analysis › Press Release
Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors
Annexon appointed Dr. Mark S. Blumenkranz, a renowned retinal surgeon and biotechnology entrepreneur, to its board of directors, effective immediately.
The appointment coincides with the departure of Muneer Satter, who steps down after more than 11 years of service.
Dr. Blumenkranz brings decades of experience in retinal therapy development, supporting Annexon as it advances its late-stage candidate vonaprument for geographic atrophy.
• 2mo ago AI analysis › Press Release ● Major ⚠ 2
Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week
Annexon reported early data from the open-label FORWARD study showing all 10 GBS patients treated with tanruprubart experienced rapid, clinically meaningful improvement in muscle strength within four days.
Specific outcomes included four bedbound patients walking within days and one ventilated patient coming off ventilation, results consistent with prior Phase 3 findings.
The company plans to use this data to support a BLA submission targeted for Q4 2026, while the MAA remains under EMA review.
• 2mo ago AI analysis › Press Release ● Major
Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance
Annexon entered into a strategic credit facility agreement with Oxford Finance for up to $200 million, providing immediate access to $50 million in non-dilutive capital.
An additional $100 million becomes available upon achieving milestones related to the registrational programs for vonaprument and tanruprubart, with the remaining $50 million subject to lender approval.
The financing diversifies the capital structure and strengthens the balance sheet as the company prepares for the potential global commercialization of its neuroinflammatory therapies.
• 3mo ago AI analysis › Press Release
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon granted inducement awards to two new non-executive employees under its 2022 Employment Inducement Award Plan, approved by the compensation committee on July 12, 2026.
In the aggregate, the employees received options to purchase 335,000 shares of common stock at an exercise price of $6.50 per share, equal to the closing price on the grant date.
The options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter.
• 3mo ago AI analysis › Press Release
Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026
Annexon announced an oral presentation at the ASRS 2026 meeting detailing baseline characteristics associated with vision loss in the Phase 2 ARCHER trial of vonaprument for geographic atrophy.
The retrospective analysis will inform patient selection for the ongoing Phase 3 ARCHER II trial, which has fully enrolled 659 patients and expects topline pivotal data in the fourth quarter of 2026.
Previous Phase 2 data demonstrated that vonaprument provided statistically significant, time and dose-dependent protection from vision loss and was generally well-tolerated.
• 3mo ago AI analysis › Press Release
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon granted inducement awards to two new non-executive employees under Nasdaq Listing Rule 5635(c)(4), approved by the compensation committee on June 13, 2026.
In the aggregate, the employees received options to purchase 705,000 shares of common stock at an exercise price of $4.64 per share, equal to the closing price on the grant date.
The options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly.
• 4mo ago AI analysis › Press Release
Annexon to Participate in Upcoming June Investor Conferences
Annexon CEO Douglas Love will participate in fireside chats at two major June healthcare conferences.
He is scheduled to speak at the Jefferies Global Healthcare Conference on June 3 in New York and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9 in Miami Beach.
Live webcasts and 30-day replays will be available on the company's investor relations website.
• 5mo ago AI analysis › Press Release
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon granted stock options to three new non-executive employees as employment inducements.
The awards cover 243,000 shares with an exercise price of $5.21, set at the May 15 closing price.
The grants were approved under Nasdaq Listing Rule 5635(c)(4) and vest over four years.
• 5mo ago AI analysis › Press Release
110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS
Annexon Biosciences partnered with GBS|CIDP Foundation International to launch the 'GBS: 110 Years, 110 Stories' campaign, aimed at raising awareness for Guillain-Barré syndrome and CIDP.
The initiative will feature 110 patient stories to highlight the need for advancements in care for these rare autoimmune disorders affecting the peripheral nerves.
Annexon is developing C1q-targeted immunotherapies designed to treat neuroinflammatory diseases, addressing a global population of nearly 10 million people.
• 5mo ago AI analysis › Press Release
Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones
Annexon reported a Q1 net loss of $44.1 million, or $0.23 per share, an improvement from the $54.4 million loss in the prior-year period, driven largely by a 26% decrease in R&D expenses to $35.8 million.
The company maintained a strong balance sheet with $225 million in cash and investments, providing an anticipated operational runway into the second half of 2027.
Pipeline milestones remain on track, with topline Phase 3 data for vonaprument in Geographic Atrophy expected in Q4 2026 and a BLA submission for tanruprubart in Guillain-Barré Syndrome anticipated later this year.
• 5mo ago AI analysis › Press Release
Annexon to Present at the Bank of America Securities Health Care Conference 2026
Annexon CEO Douglas Love is scheduled to present at the Bank of America Securities Health Care Conference on May 13, 2026.
A live webcast will be available on the company's website, with a replay archived for 30 days following the event.
The announcement contains no financial or clinical updates, serving solely as a logistical notice for the upcoming presentation.
• 5mo ago AI analysis › Press Release
Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference
globenewswire.com • 6mo ago Press Release ● Major
Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
globenewswire.com • 7mo ago 
